CD34 and type 2 diabetes mellitus: Regarding thiazolidinediones, a 12-week treatment of recently diagnosed T2DM patients with rosiglitazone reduced glucose levels, increased EPCs number (CD34+CD133+) and improved its migratory ability [172].